Protalix BioTherapeutics, Inc. (PLX)
USD 1.71
(-1.72%)
USD 1.71
(-1.72%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 26.28 Million USD | -21.49% |
| 2022 | 33.47 Million USD | 0.01% |
| 2021 | 33.47 Million USD | -48.03% |
| 2020 | 64.4 Million USD | 5.7% |
| 2019 | 60.92 Million USD | 27.02% |
| 2018 | 47.96 Million USD | -8.09% |
| 2017 | 52.18 Million USD | -32.67% |
| 2016 | 77.51 Million USD | 7.52% |
| 2015 | 72.09 Million USD | 6.87% |
| 2014 | 67.46 Million USD | 0.62% |
| 2013 | 67.04 Million USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 57.83 Thousand USD | -9.83% |
| 1998 | 64.13 Thousand USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 26.37 Million USD | 0.35% |
| 2024 Q2 | 26.15 Million USD | -0.83% |
| 2023 Q4 | 26.28 Million USD | 1.05% |
| 2023 FY | 26.28 Million USD | -21.49% |
| 2023 Q1 | 33.56 Million USD | 0.28% |
| 2023 Q2 | 25.96 Million USD | -22.64% |
| 2023 Q3 | 26 Million USD | 0.15% |
| 2022 Q4 | 33.47 Million USD | 1.0% |
| 2022 Q2 | 33 Million USD | -1.16% |
| 2022 Q3 | 33.14 Million USD | 0.4% |
| 2022 Q1 | 33.39 Million USD | -0.22% |
| 2022 FY | 33.47 Million USD | 0.01% |
| 2021 Q3 | 36.73 Million USD | -40.85% |
| 2021 Q1 | 61.07 Million USD | -5.16% |
| 2021 FY | 33.47 Million USD | -48.03% |
| 2021 Q4 | 33.47 Million USD | -8.88% |
| 2021 Q2 | 62.09 Million USD | 1.67% |
| 2020 Q4 | 64.4 Million USD | 1.35% |
| 2020 FY | 64.4 Million USD | 5.7% |
| 2020 Q1 | 61.68 Million USD | 1.25% |
| 2020 Q2 | 62.59 Million USD | 1.47% |
| 2020 Q3 | 63.54 Million USD | 1.51% |
| 2019 Q2 | 55.19 Million USD | 1.41% |
| 2019 Q3 | 55.91 Million USD | 1.31% |
| 2019 Q4 | 60.92 Million USD | 8.96% |
| 2019 Q1 | 54.42 Million USD | 13.47% |
| 2019 FY | 60.92 Million USD | 27.02% |
| 2018 Q3 | 47.32 Million USD | 1.24% |
| 2018 FY | 47.96 Million USD | -8.09% |
| 2018 Q4 | 47.96 Million USD | 1.37% |
| 2018 Q2 | 46.74 Million USD | -10.18% |
| 2018 Q1 | 52.03 Million USD | -0.29% |
| 2017 FY | 52.18 Million USD | -32.67% |
| 2017 Q3 | 63.83 Million USD | 10.29% |
| 2017 Q1 | 117.5 Million USD | 51.59% |
| 2017 Q4 | 52.18 Million USD | -18.25% |
| 2017 Q2 | 57.88 Million USD | -50.74% |
| 2016 FY | 77.51 Million USD | 7.52% |
| 2016 Q1 | 72.2 Million USD | 0.15% |
| 2016 Q2 | 72.31 Million USD | 0.15% |
| 2016 Q3 | 72.43 Million USD | 0.15% |
| 2016 Q4 | 77.51 Million USD | 7.02% |
| 2015 Q4 | 72.09 Million USD | 6.38% |
| 2015 Q3 | 67.77 Million USD | 0.15% |
| 2015 FY | 72.09 Million USD | 6.87% |
| 2015 Q1 | 67.56 Million USD | 0.15% |
| 2015 Q2 | 67.67 Million USD | 0.15% |
| 2014 FY | 67.46 Million USD | 0.62% |
| 2014 Q1 | 67.15 Million USD | 0.15% |
| 2014 Q4 | 67.46 Million USD | 0.16% |
| 2014 Q3 | 67.35 Million USD | 0.15% |
| 2014 Q2 | 67.25 Million USD | 0.15% |
| 2013 Q4 | 67.04 Million USD | 0.16% |
| 2013 Q3 | 66.94 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 67.04 Million USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q2 | 4.68 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | 4.45 Million USD | 0.0% |
| 2011 Q3 | - USD | -100.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q1 | 57.83 Thousand USD | 0.0% |
| 2000 Q2 | 57.83 Thousand USD | 0.0% |
| 2000 Q4 | - USD | -100.0% |
| 2000 Q3 | 22.83 Thousand USD | -60.52% |
| 1999 FY | 57.83 Thousand USD | -9.83% |
| 1999 Q1 | 57.83 Thousand USD | -42.17% |
| 1999 Q3 | 57.83 Thousand USD | 0.0% |
| 1999 Q4 | 57.83 Thousand USD | 0.0% |
| 1999 Q2 | 57.83 Thousand USD | 0.0% |
| 1998 Q4 | 100 Thousand USD | 0.0% |
| 1998 Q1 | - USD | -100.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 64.13 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | 500 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -5209.293% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | -9491.606% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 78.167% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | -1143.777% |
| Azitra, Inc. | 885.94 Thousand USD | -2866.43% |
| Can-Fite BioPharma Ltd. | 39.99 Thousand USD | -65604.143% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | -1971.515% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | -263.198% |
| CEL-SCI Corporation | 13.57 Million USD | -93.645% |
| iBio, Inc. | 4.46 Million USD | -489.26% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | -790.278% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | -639.061% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | -979.61% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | -859.161% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | -8304.46% |
| BiomX Inc. | 15.09 Million USD | -74.139% |
| BiomX Inc. | 15.09 Million USD | -74.139% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | -4351.856% |
| Scorpius Holdings, Inc. | 14.04 Million USD | -87.159% |